» Articles » PMID: 33005597

Standardization of the First Korean National Reference Standard for Snake () Antivenom

Overview
Journal Toxicol Res
Specialty Toxicology
Date 2020 Oct 2
PMID 33005597
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

In 2017, the second national reference standard (NRS) for Gloydius snake venom was established to replace the first NRS for Gloydius snake venom. In connection with the second venom NRS, a candidate for the first NRS for Gloydius snake antivenom was produced in 2017. In this study, the qualification of the candidate was estimated and the potency was determined by a collaborative study. The potency (anti-lethal titer and anti-hemorrhagic titer) of the candidate was determined by measuring the capability of the antivenom to neutralize the lethal and hemorrhagic effects of the second NRS for Gloydius snake venom, which was calibrated against the regional reference standard for Gloydius snake antivenom established in 2006. Two Korean facilities contributed data from 20 independent assays. Subsequently, one foreign national control research laboratories participated in this collaborative study. The general common potency of the anti-lethal and anti-hemorrhagic titers was obtained from the results of a total of 25 tests performed at three facilities. According to the results of the present study, the candidate preparation showed good quality and is judged to be suitable to serve as the first NRS for Gloydius snake antivenom with the following potency: an anti-lethal titer of 3100 unit (U) (95% confidence interval 2991-3276 U) and anti-hemorrhagic titer of 3000 U (95% confidence interval 2849-3159 U). In conclusion, the first NRS for Gloydius snake antivenom was established in this study. This reference standard will be used routinely for quality control of a snake antivenom product by manufacturer in Korea, which also can be used for national quality control, including a national lot-release test of the snake antivenom product.

Citing Articles

Snakebite Management: The Need of Reassessment, International Relations, and Effective Economic Measures to Reduce the Considerable SBE Burden.

Kumar R, Rathore A J Epidemiol Glob Health. 2024; 14(3):586-612.

PMID: 38856820 PMC: 11442967. DOI: 10.1007/s44197-024-00247-z.


Report on the seventh meeting of national control laboratories for vaccines and biologicals of the WHO Western Pacific and South-East Asia member states.

Shim S, Choi C, Shin J, Kim J, Schepelmann S, Jung J Biologicals. 2023; 84:101712.

PMID: 37797484 PMC: 10719889. DOI: 10.1016/j.biologicals.2023.101712.


A Retrospective Evaluation of Snake Envenomation in Dogs in South Korea (2004-2021).

Lee J, Song J, Song K Toxins (Basel). 2022; 14(8).

PMID: 36006225 PMC: 9415592. DOI: 10.3390/toxins14080565.


Adverse Reactions after Administration of Antivenom in Korea.

Shim J, Kang H, Cho Y, Shin H, Lee H Toxins (Basel). 2020; 12(8).

PMID: 32781766 PMC: 7472312. DOI: 10.3390/toxins12080507.

References
1.
Omori T, Iwanaga S, Suzuki T . THE RELATIONSHIP BETWEEN THE HEMORRHAGIC AND LETHAL ACTIVITIES OF JAPANESE MAMUSHI (AGKISTRODON HALYS BLOMHOFFII) VENOM. Toxicon. 1964; 15:1-4. DOI: 10.1016/0041-0101(64)90027-3. View

2.
Fukuda T, Iwaki M, Hong S, Oh H, Wei Z, Morokuma K . Standardization of regional reference for mamushi (Gloydius blomhoffii) antivenom in Japan, Korea, and China. Jpn J Infect Dis. 2006; 59(1):20-4. View

3.
Gutierrez J, Leon G, Lomonte B, Angulo Y . Antivenoms for snakebite envenomings. Inflamm Allergy Drug Targets. 2011; 10(5):369-80. DOI: 10.2174/187152811797200669. View

4.
Kasturiratne A, Wickremasinghe A, de Silva N, Gunawardena N, Pathmeswaran A, Premaratna R . The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med. 2008; 5(11):e218. PMC: 2577696. DOI: 10.1371/journal.pmed.0050218. View

5.
Eble J . Matrix biology meets toxinology. Matrix Biol. 2010; 29(4):239-47. DOI: 10.1016/j.matbio.2010.01.004. View